Sg3 Management, LLC Argenx Se Call Options Transaction History

Sg3 Management, LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2021 Aug 16, 2021	SELL	$257.11 - $319.92 $5.78 Million - $7.2 Million	-22,500 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$268.3 - $380.31 $4.02 Million - $5.7 Million	15,000 Added 200.0%	22,500 $6.2 Million
Q4 2020 Feb 16, 2021	SELL	$248.13 - $308.36 $620,325 - $770,900	-2,500 Reduced 25.0%	7,500 $2.21 Million
Q3 2020 Nov 13, 2020	BUY	$215.51 - $272.51 $258,612 - $327,012	1,200 Added 13.64%	10,000 $2.63 Million
Q2 2020 Aug 14, 2020	BUY	$127.44 - $232.72 $1.12 Million - $2.05 Million	8,800 New	8,800 $1.98 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.9B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.